Publication: Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis
Issued Date
2000-08-12
Resource Type
ISSN
00221899
DOI
Other identifier(s)
2-s2.0-0033930348
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Infectious Diseases. Vol.182, No.1 (2000), 371-374
Suggested Citation
George Watt, Supachai Saisorn, Krisada Jongsakul, Yuwaporn Sakolvaree, Wanpen Chaicumpa Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis. Journal of Infectious Diseases. Vol.182, No.1 (2000), 371-374. doi:10.1086/315645 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26192
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis
Abstract
There is no consensus on the benefits of treatment with any specific anthelminthic compound on muscle-stage trichinosis. A double-blind, placebo- controlled comparison was done of 3 antiparasitic drugs during an outbreak of trichinosis in Chiangrai Province, northern Thailand. Forty-six adults were randomized to receive 10 days of oral treatment with mebendazole (200 mg twice a day), thiabendazole (25 mg/kg twice a day), fluconazole (400 mg initially, then 200 mg daily), or placebo. All patients received treatment to eradicate adult intestinal worms. Trichinella spiralis infection was proved parasitologically in 19 (41%) of 46 patient and by serodiagnosis in all cases. Significantly more patients imprOVed after treatment with mebendazole (12/12) and thiabendazole (7/7) than after treatment with placebo (6/12; P < .05) or fluconazole (6/12). Muscle tenderness resolved in more patients treated with thiabendazole and mebendazole than in those treated with placebo (P < .05). However, 30% of volunteers could not tolerate the side effects of thiabendazole. In summary, Trichinella myositis responds to thiabendazole and to mebendazole.